Yahoo Finance

TURKU, FINLAND / ACCESS Newswire / March 21, 2025 / Faron Pharmaceuticals (HEL:FARON)(LSE:FARN)(AIM: FARN) (First North: FARON), a clinical-stage biopharmaceutical company pursuing a CLEVER approach to reprogramming myeloid cells to activate anti-tumor immunity in hematological and solid tumor microenvironments, is pleased to announce the appointment of Dr Juho Jalkanen to the Board of Directors as an Executive Director and Mr. Colin Bond to the Board of Directors as a Non-executive Director of the Company with immediate effect following the passing of all resolutions put to shareholders of the Company at the Annual General Meeting held earlier today.

Mr Bond has a wealth of international experience in contract development and manufacturing organisations ("CDMO") and biopharma industries and was most recently Chief Financial Officer of Sandoz listed on the SIX Swiss Exchange, where he played a key role in the company's successful spin-off from Novartis. Prior to Sandoz, Mr. Bond was Chief Financial Officer of Vifor Pharma Management AG and Evotec AG. He also served as Chair of the Audit Committee for Siegfried AG, a leading CDMO quoted on the SIX Swiss Exchange, for ten years until May 2023. Mr. Bond is Chair of the Audit Committee of BioPharma Credit PLC on the London Stock Exchange, and currently serves as a Non-executive Director at Medichem SA since 2025, Oxford Biomedica PLC since 2025, Agomab Therapeutics NV since 2024 and Formycon AG since 2024.

During his early career, Mr. Bond worked as a pharmacist, auditor and management consultant for Procter & Gamble, Arthur Andersen and PwC. Mr. Bond is a Fellow of the Institute of Chartered Accountants in England and Wales and a Member of the Royal Pharmaceutical Society of Great Britain. He holds a BSc in Pharmacy from Aston University and an MBA from London Business School.

Mr Bond graduated from Aston University in 1984 with a BSc Pharmacy and began his career with Proctor & Gamble working as a pharmacist, and he subsequently moved to Arthur Anderson & Co, qualifying as a chartered accountant and was admitted to the Institute of Chartered Accountants in England & Wales (ICAEW) in 1991. He undertook an MBA at London Business School in 1996.

The following information regarding the appointment of Mr. Colin Michael Bond (age 65) is disclosed under Schedule 2(g) of the AIM Rules for Companies and Nasdaq First North Growth Market Rulebook.

Mr. Bond holds no ordinary shares or options or warrants over ordinary shares in the Company.